The latest price target for Lifecore Biomedical (NASDAQ:LFCR) was reported by Barrington Research on September 1, 2023. The analyst firm set a price target for $10.00 expecting LFCR to rise to within 12 months (a possible 85.19% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Lifecore Biomedical (NASDAQ:LFCR) was provided by Barrington Research, and Lifecore Biomedical maintained their outperform rating.

There is no last upgrade for Lifecore Biomedical

The last downgrade for Lifecore Biomedical Inc happened on March 20, 2023 when Stephens & Co. changed their price target from $11 to $2 for Lifecore Biomedical Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lifecore Biomedical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lifecore Biomedical was filed on September 1, 2023 so you should expect the next rating to be made available sometime around September 1, 2024.

While ratings are subjective and will change, the latest Lifecore Biomedical (LFCR) rating was a maintained with a price target of $11.00 to $10.00. The current price Lifecore Biomedical (LFCR) is trading at is $5.40, which is out of the analyst’s predicted range.